Novel Compound Reduces Lung and Heart Damage from SARS-CoV-2 Infection

The SARS-CoV-2 virus, responsible for COVID-19, often causes severe cardiopulmonary injury, leading to significant morbidity and mortality. Current treatments primarily focus on antiviral effects or symptom management, but there remains a critical need for therapies that directly mitigate organ damage. This study specifically addresses whether targeting the growth hormone-releasing hormone (GHRH) receptor with an antagonist can protect against SARS-CoV-2-induced heart and lung damage.

Treatment with MIA-602 significantly attenuated the severe cardiopulmonary pathology induced by SARS-CoV-2 infection. Histopathological analysis of lung tissue revealed a 43% reduction in inflammatory cell infiltration and a 55% decrease in alveolar damage scores in MIA-602-treated mice compared to untreated infected controls (p<0.001). Furthermore, cardiac injury markers, such as serum troponin-I levels, were reduced by 38% in the treated group (p<0.01). The most significant finding was a 62% reduction in overall lung injury scores and a 2.8-fold decrease in viral load in the lungs of mice receiving MIA-602, indicating potent protective effects against severe SARS-CoV-2 pathology. This suggests that GHRH receptor antagonism can directly mitigate both inflammation and viral replication, leading to improved organ function.